GSK Merger Helps CNS Breathe Easier About Breathe Right Patent Expiration
This article was originally published in The Tan Sheet
Executive Summary
CNS sees its proposed acquisition by Glaxo as an opportunity to protect the intellectual property rights and market share of its Breathe Right brand with the additional resources available to a larger company